Literature DB >> 25083440

How transferable are recommendations of the era of treating conventionally defined breast cancer for the era of molecularly characterised breast cancer?

Robert Königsberg1, Christian Dittrich1.   

Abstract

Entities:  

Year:  2012        PMID： 25083440      PMCID： PMC4115702          DOI： 10.3978/j.issn.2227-684X.2012.10.02

Source DB:  PubMed          Journal:  Gland Surg        ISSN： 2227-684X


× No keyword cloud information.
  14 in total

Review 1.  Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer.

Authors:  Philippe L Bedard; Angelo Di Leo; Martine J Piccart-Gebhart
Journal:  Nat Rev Clin Oncol       Date:  2009-12-08       Impact factor: 66.675

2.  Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.

Authors:  Lawrence N Shulman; Constance T Cirrincione; Donald A Berry; Heather P Becker; Edith A Perez; Ruth O'Regan; Silvana Martino; James N Atkins; Erica Mayer; Charles J Schneider; Gretchen Kimmick; Larry Norton; Hyman Muss; Eric P Winer; Clifford Hudis
Journal:  J Clin Oncol       Date:  2012-07-23       Impact factor: 44.544

3.  Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.

Authors:  B Fisher; A M Brown; N V Dimitrov; R Poisson; C Redmond; R G Margolese; D Bowman; N Wolmark; D L Wickerham; C G Kardinal
Journal:  J Clin Oncol       Date:  1990-09       Impact factor: 44.544

4.  Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.

Authors:  Stephen E Jones; Michael A Savin; Frankie Ann Holmes; Joyce A O'Shaughnessy; Joanne L Blum; Svetislava Vukelja; Kristi J McIntyre; John E Pippen; James H Bordelon; Robert Kirby; John Sandbach; William J Hyman; Pankaj Khandelwal; Angel G Negron; Donald A Richards; Stephen P Anthony; Robert G Mennel; Kristi A Boehm; Walter G Meyer; Lina Asmar
Journal:  J Clin Oncol       Date:  2006-12-01       Impact factor: 44.544

5.  Adjuvant trastuzumab in HER2-positive breast cancer.

Authors:  Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown
Journal:  N Engl J Med       Date:  2011-10-06       Impact factor: 91.245

6.  Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Authors:  Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

7.  Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.

Authors:  Michele De Laurentiis; Giuseppe Cancello; Diego D'Agostino; Mario Giuliano; Antonio Giordano; Emilia Montagna; Rossella Lauria; Valeria Forestieri; Angela Esposito; Lucrezia Silvestro; Roberta Pennacchio; Carmen Criscitiello; Agnese Montanino; Gennaro Limite; Angelo Raffaele Bianco; Sabino De Placido
Journal:  J Clin Oncol       Date:  2008-01-01       Impact factor: 44.544

Review 8.  Role of anthracyclines in the treatment of early breast cancer.

Authors:  Luca Gianni; Larry Norton; Norman Wolmark; Thomas M Suter; Gianni Bonadonna; Gabriel N Hortobagyi
Journal:  J Clin Oncol       Date:  2009-08-17       Impact factor: 44.544

Review 9.  Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer.

Authors:  Sumanta K Pal; Barrett H Childs; Mark Pegram
Journal:  Breast Cancer Res Treat       Date:  2010-01       Impact factor: 4.872

10.  Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.

Authors:  A Goldhirsch; W C Wood; A S Coates; R D Gelber; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2011-06-27       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.